A tiny protein might be the master key to neurodegeneration

Health · Published 18 October 2026 Swipe more like this →

In short: Alpha-synuclein is a small protein essential for brain communication. But when it misfolds, it triggers a cascade of cellular failure. Understanding its transition from a functional messenger to a toxic aggregate is the frontier for treating Parkinson’s and other devastating neurological disorders.

Alpha-synuclein (α-syn) is a 14 KDa acidic protein primarily found in the brain, where it resides at the tips of neurons in presynaptic terminals. Its primary job is maintaining an adequate supply of synaptic vesicles and regulating the release of neurotransmitters like dopamine, which controls voluntary and involuntary movements. It also plays a role in microtubule movement to help cells maintain their shape.

The pathology begins when α-syn adopts abnormal forms, such as pathological β-sheet conformations. These can form oligomers or amyloid fibrils that aggregate into Lewy bodies (LB) or Lewy neurites. In Multiple System Atrophy (MSA), these aggregates primarily form in glial cytoplasmic inclusions called Papp-Lantos bodies. This misfolding is not just a structural fluke; it triggers selective neuronal death by impairing mitochondria, disrupting lysosomal function, and altering calcium homeostasis.

Research suggests that inflammation may actually precede the deposition of α-syn, creating a mechanistic link between early immune responses and synaptic dysfunction. Furthermore, secreted α-syn can 'seed' aggregation in neighboring cells, potentially explaining how these diseases spread through the nervous system. Because the SNCA gene encodes this protein, identifying specific genetic variations is crucial for understanding why some individuals are more susceptible to synucleinopathies like Dementia with Lewy Bodies or REM sleep behavior disorder.

Current therapeutic research is moving beyond just clearing aggregates. Scientists are exploring passive and active immunization, as well as modulators of protein aggregation, to intervene before overt neurodegeneration occurs. By targeting the early synaptic alterations and inflammation that precede cell death, researchers hope to develop disease-modifying therapies for a broad range of synucleinopathies.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Could tiny molecules within our cells be the key to reversing Alzheimer's disease?
• Soluble amyloid-β and tau may jointly drive Alzheimer's before plaques form
• The cellular clumps that hold the secrets to neurodegeneration and biotechnology
• A decade of research links misfolded proteins to Alzheimer's and diabetes
• The cellular breakdown of the brain is more than just aging
• Can your wearable tell if you are becoming depressed?
• The mathematical ghost in your biology: why biorhythms failed the test
• Your body has a natural clock that ignores your alarm
• Is bed-sharing a dangerous risk or a vital evolutionary tool?
• The math of kinship: How we calculate biological relatedness
• While you sleep, your brain rinses itself.
• The biological cost of the 24-hour economy: Shift Work Sleep Disorder

More in Sleep · More in Health · Latest · A–Z · All topics